Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6766373 | 0.89 | KMT2A (0.41) | OPRM1ALDH1A1HDAC4MAPTKDM4E | |
| SCHEMBL6850209 | 0.87 | OPRM1 (0.40) | OPRM1ALDH1A1CXCR2 | |
| SCHEMBL6765932 | 0.87 | S1PR5 (0.43) | OPRM1 | |
| SCHEMBL7160989 | 0.85 | OPRM1 (0.49) | OPRM1ALDH1A1KDM4EKMT2AMEN1 | |
| SCHEMBL27445509 | 0.81 | ALDH1A1 (0.38) | OPRM1ALDH1A1CXCR2MAPTKDM4E | |
| SCHEMBL6765258 | 0.78 | OPRM1 (0.41) | OPRM1 | |
| SCHEMBL6850630 | 0.77 | MEN1 (0.41) | OPRM1ALDH1A1MAPTKDM4EGFER | |
| SCHEMBL6766826 | 0.77 | CACNA1C (0.48) | OPRM1 | |
| SCHEMBL6762559 | 0.73 | ALOX15 (0.36) | OPRM1MAPT | |
| SCHEMBL6771757 | 0.71 | OPRM1 (0.41) | OPRM1ALDH1A1KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774133-B2 | Substituted spiroheterocyclic 1H-3-aryl-pyrrolidine-2,4-dione derivatives, processes for their preparation, and their use as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2004-08-10 | — | — | US | disclosed |
| US-20040009999-A1 | Substituted spiroheterocyclic 1H-3-aryl-pyrrolidine-2,4-dione derivatives, processes for their preparation, and their use as pesticides | FISCHER REINER (DE) | 2004-01-15 | — | — | US | disclosed |
| US-6555567-B1 | 2-oxo-3-aryl-4-hydroxy-1-aza-8-thiaspiro(4.5)decane derivatives of given formula; use as arthropodicide or nematicide | BAYER AKTIENGESELLSCHAFT (DE) | 2003-04-29 | — | — | US | disclosed |
| CN-1099420-C | Substituted spiroheterocyclic 1H-3-arylpyrrolidine-2,4-dione derivatives, methods of preparing them and their use as pest-control agents | BAYER AG (DE) | 2003-01-22 | — | — | CN | disclosed |
| US-6479489-B1 | AN ARTHROPODICIDAL OR NEMATICIDAL COMPOSITION | BAYER AKTIENGESELLSCHAFT (DE) | 2002-11-12 | — | — | US | disclosed |
| US-5981567-A | ARTHROPODICIDAL OR NEMATICIDAL COMPOSITION | BAYER AKTIENGESELLSCHAFT (DE) | 1999-11-09 | — | — | US | disclosed |
| CN-1126475-A | Substituted spiroheterocyclic 1H-3-arylpyrrolidine-2,4-dione derivatives, methods of preparing them and their use as pest-control agents | BAYER AG (DE) | 1996-07-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009999-A1 | Substituted spiroheterocyclic 1H-3-aryl-pyrrolidine-2,4-dione derivatives, processes for their preparation, and their use as pesticides | DDT, HPD, CAT | OPRM1 2117/4885ALDH1A1 382/4885HDAC4 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.